The significant revenue growth and pipeline progress are positive, but the widening loss and high operating expenses warrant monitoring. The successful convertible note issuance strengthens the balance sheet for upcoming commercial launches. Traders should watch for NDA submissions in 1H 2026 and commercial execution of Attruby, which showed 35% QoQ growth in Q4.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $66.54entry
- T+1 · 9mo ago +1.61%α +2.15% · $67.61
- T+5 · 9mo ago 0.00%α +1.10% · $66.54
- T+20 · 8mo ago +7.62%α +12.86% · $71.61
- T+60 · 6mo ago +2.52%α −4.43% · $68.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio Pharma reported strong 2025 financial results driven by $502.1 million in net revenue, primarily from its ATTR-CM drug Attruby, which generated $362.4 million in net product revenue. The company achieved three positive Phase 3 trial readouts, secured $632.5 million in convertible notes, and maintained a robust pipeline with multiple near-term NDA submissions. Despite revenue growth, net loss widened to $724.9 million due to increased commercial and R&D investments.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $154.2 million (up from $5.9 million YoY), full year revenue: $502.1 million (up from $221.9 million YoY)
- Attruby net product revenue: $146.0 million in Q4, $362.4 million for full year 2025
- Three positive Phase 3 readouts: BBP-418 (LGMD2IR9), encaleret (ADH1), and infigratinib (achondroplasia)
- Cash position: $587.5 million as of December 31, 2025, plus $632.5 million from January 2026 convertible notes issuance
- Net loss attributable to common stockholders: $724.9 million for 2025 (vs $535.8 million in 2024)
Financial Impact
Revenue increased by $280.2 million YoY, driven by $359.5 million growth in Attruby sales, but operating expenses rose $210.6 million to $1.0 billion
Segment Breakdown
| Segment | Revenue |
|---|---|
| Attruby | $362.4M |
Risk Factors
- Increasing operating losses despite revenue growth
- High dependence on Attruby sales with competitive risks
- Execution risk in upcoming NDA submissions and product launches
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001743881-26-000008 |
| Document: bbio-20260224.htm | 0001743881-26-000008 |
| Document: 0001743881-26-000008-index-headers.html | 0001743881-26-000008 |
| Document: 0001743881-26-000008-index.html | 0001743881-26-000008 |
| Document: 0001743881-26-000008.txt | 0001743881-26-000008 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers